Marker Therapeutics Announces $16.1 Million Private Placement
Portfolio Pulse from
Marker Therapeutics has announced a $16.1 million private placement to support the clinical advancement of its Phase 1 APOLLO study. This study investigates MT-601 in patients with lymphoma who have relapsed after anti-CD19 CAR-T cell therapy.
December 19, 2024 | 1:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Marker Therapeutics has raised $16.1 million through a private placement to fund its Phase 1 APOLLO study, which focuses on MT-601 for lymphoma patients relapsed after anti-CD19 CAR-T therapy.
The $16.1 million private placement provides Marker Therapeutics with the necessary funds to continue its clinical trials, which is a positive development for the company. This could lead to advancements in their MT-601 therapy, potentially increasing investor confidence and positively impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100